RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients

@inproceedings{Kachnic2013RTOG0R,
  title={RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients},
  author={Lisa Ann Kachnic and Stephanie L. Pugh and Patricia Tai and Matthew D. Smith and Elizabeth M. Gore and Amit B. Shah and Andr{\'e}-Guy Martin and Harold E. Kim and Abdenour Nabid and Colleen AF Lawton},
  booktitle={Prostate Cancer and Prostatic Disease},
  year={2013}
}
Background:RTOG 0518 evaluated the potential benefit of zoledronic acid therapy in preventing bone fractures for patients with high grade and/or locally advanced, non-metastatic prostate adenocarcinoma receiving luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy (RT).Methods:Eligible patients with T-scores of the hip (<−1.0, but >−2.5 vs >−1.0) and negative bone scans were prospectively randomized to either zoledronic acid, 4 mg, concurrently with the start of RT and then… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Similar Papers

Loading similar papers…